Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 23 Mar 2026

Intraday Performance and Price Movement

The pharmaceutical major saw its stock price fall by 3.02% during the trading session, slightly underperforming the Sensex which declined by 1.99% on the same day. The stock’s intraday low of Rs 1260.05 marked a significant price pressure point, representing a near 3% dip from its prior close. Despite this, Dr Reddys Laboratories marginally outperformed its sector, Pharmaceuticals & Biotechnology, which declined by 3.18% on the day.

Technical indicators reveal a mixed picture. The stock currently trades above its 50-day and 100-day moving averages, signalling some medium-term support. However, it remains below its 5-day, 20-day, and 200-day moving averages, indicating short-term weakness and a lack of upward momentum. This positioning suggests that while the stock has some resilience, immediate pressures are limiting its ability to sustain gains.

Market and Sector Context

The broader market environment has been challenging. The Sensex opened sharply lower, down 800.38 points, and continued to fall by an additional 735.80 points to close at 72,996.78, a 2.06% decline. This places the benchmark index just 2.15% above its 52-week low of 71,425.01, underscoring the prevailing bearish sentiment. The Sensex is trading below its 50-day moving average, which itself is positioned below the 200-day moving average, a classic bearish technical setup. Furthermore, the index has recorded losses of 7.5% over the past three weeks, reflecting sustained selling pressure.

Within this environment, the Pharmaceuticals & Biotechnology sector has not been immune to selling, with a 3.18% decline on the day. Dr Reddys Laboratories’ performance, while negative, was slightly better than the sector average, indicating relative stability amid sector-wide weakness.

Performance Trends and Relative Strength

Examining Dr Reddys Laboratories’ recent performance relative to the Sensex reveals a nuanced trend. Over the past week, the stock declined by 1.20%, outperforming the Sensex’s 3.25% drop. Over one month, the stock’s loss of 3.62% was considerably less severe than the Sensex’s 12.30% decline. Similarly, over three months, Dr Reddys Laboratories fell by 1.82%, while the Sensex dropped 14.59%. These figures suggest that despite the intraday weakness, the stock has demonstrated relative resilience over medium-term periods.

On a longer horizon, the stock’s one-year performance shows a 4.88% gain compared to the Sensex’s 5.02% loss, and year-to-date it has declined by 0.89%, outperforming the Sensex’s 14.29% fall. Over three years, Dr Reddys Laboratories has appreciated by 41.60%, outpacing the Sensex’s 26.10% gain, though over five and ten years, the Sensex has outperformed the stock with returns of 45.94% and 188.29% respectively, compared to 44.07% and 106.69% for Dr Reddys Laboratories.

Technical Indicators and Market Sentiment

Technical analysis presents a mixed outlook. The daily moving averages suggest a mildly bearish stance, consistent with the recent price pressure. Weekly indicators such as MACD and Bollinger Bands are bullish, while monthly MACD and KST indicators are mildly bearish, reflecting some caution in longer-term momentum. The Dow Theory readings are mildly bullish on both weekly and monthly timeframes, indicating some underlying strength despite short-term weakness. The On-Balance Volume (OBV) is mildly bearish weekly and shows no clear trend monthly, suggesting volume patterns are not decisively supporting a strong directional move.

Overall, these technical signals align with the observed price action: the stock is experiencing short-term selling pressure amid a cautious market environment but retains some medium-term support and relative strength within its sector.

Mojo Score and Rating Update

Dr Reddys Laboratories currently holds a Mojo Score of 54.0, categorised as a Hold rating. This represents an improvement from its previous Sell rating, which was updated on 16 Mar 2026. The stock is classified as a large-cap company within the Pharmaceuticals & Biotechnology sector, reflecting its established market presence and scale. The Hold rating indicates a neutral stance based on the current assessment of financial metrics, trend analysis, and quality grades.

This rating change suggests some stabilisation in the company’s outlook, although the stock remains subject to the prevailing market and sector headwinds that have influenced its intraday price movements.

Summary of Market Pressures

The intraday decline in Dr Reddys Laboratories’ stock price is primarily attributable to the broader market downturn and sector-specific weakness. The Sensex’s sharp fall and proximity to its 52-week low have created a cautious trading environment. The Pharmaceuticals & Biotechnology sector’s decline of 3.18% further compounded selling pressure on the stock. Technical indicators confirm short-term bearishness, while medium-term signals provide some support.

In this context, the stock’s intraday low of Rs 1260.05 reflects the immediate pressures faced by Dr Reddys Laboratories, as investors navigate a challenging market landscape marked by sustained selling and cautious sentiment.

Conclusion

Dr Reddys Laboratories Ltd’s intraday low on 23 Mar 2026 highlights the stock’s vulnerability to current market and sector dynamics. While the stock has shown relative resilience over longer periods, the immediate price pressure and technical signals indicate a cautious near-term outlook. The Hold rating and Mojo Score of 54.0 reflect a balanced view amid these conditions. Investors and market participants will continue to monitor the stock’s performance within the context of ongoing market volatility and sector trends.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →